FDA approves Genentech drug for advanced lung cancer

The Food and Drug Administration has approved an experimental Genetech drug for patients with a certain type of lung cancer who have few other options. Alecensa (AL’-eh-sehn-sah) was approved for patients with advanced non-small cell lung cancer with a mutation in a gene called ALK who have relapsed after treatment with Pfizer Inc.’s Xalkori or […]